Claims for Patent: 6,652,854
✉ Email this page to a colleague
Summary for Patent: 6,652,854
Title: | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
Abstract: | The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF.alpha. inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF.alpha. inhibitors. |
Inventor(s): | Mohler; Kendall M. (Poulsbo, WA), Barone; Dauphine S. (Everett, WA), Kennedy; Mary K. (Seattle, WA) |
Assignee: | Immunex Corporation (Seattle, WA) |
Application Number: | 09/921,667 |
Patent Claims: | 1. A method of treating multiple sclerosis, rheumatoid arthritis or systemic lupus erythematosous in a patient, said method comprising administering to the patient an agent
that comprises an antibody that is specific for CD30L, wherein the agent is administered according to a regimen of dose and frequency of administration that is adequate to induce a sustained improvement in at least one indicator that reflects the
severity of the patient's condition, the improvement being considered sustained if the patient exhibits the improvement on at least two occasions separated by at least one day.
2. A method according to claim 1, wherein the patient is a human. 3. A method according to claim 2, wherein the condition is rheumatoid arthritis. 4. A method according to claim 1, wherein the agent is administered concurrently with a second agent that is an antagonist of TNF.alpha., and further wherein the patient's condition is selected from the group consisting of rheumatoid arthritis and systemic lupus erythematosous. 5. A method according to claim 2, wherein the patient's condition is multiple sclerosis. 6. A method according to claim 2, wherein the patient's condition is systemic lupus erythematosus. 7. A method according to claim 1, wherein the antibody specific for CD30L is a monoclonal antibody. 8. A method according to claim 1, wherein the antibody specific for CD30L is a humanized antibody. 9. A method according to claim 1, wherein the antibody specific for CD30L is a human antibody. 10. A method according to claim 4, wherein the antagonist of TNF.alpha. is selected from the group consisting of etanercept, p55 TNFR-Ig fusion protein and an antibody against TNF.alpha.. 11. A method according to claim 10, wherein the antagonist of TNF.alpha. is an antibody against TNF.alpha., and further wherein said antibody is selected from the group consisting of infliximab, D2E7 and CDP571. 12. A method according to claim 1, wherein said agent further comprises a physiologically acceptable carrier, excipient and/or diluent. 13. A method according to claim 4, wherein the antibody specific for CD30L is a monoclonal antibody. 14. A method according to claim 4, wherein the antibody specific for CD30L is a humanized antibody. 15. A method according to claim 4, wherein the antibody specific for CD30L is a human antibody. 16. A method according to claim 3, wherein the antibody specific for CD30L is a monoclonal antibody. 17. A method according to claim 3, wherein the antibody specific for CD30L is a humanized antibody. 18. A method according to claim 3, wherein the antibody specific for CD30L is a human antibody. 19. A method according to claim 5, wherein the antibody specific for CD30L is a monoclonal antibody. 20. A method according to claim 5, wherein the antibody specific for CD30L is a humanized antibody. 21. A method according to claim 5, wherein the antibody specific for CD30L is a human antibody. 22. A method according to claim 6, wherein the antibody specific for CD30L is a monoclonal antibody. 23. A method according to claim 6, wherein the antibody specific for CD30L is a humanized antibody. 24. A method according to claim 6, wherein the antibody specific for CD30L is a human antibody. |
Details for Patent 6,652,854
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2020-08-08 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2020-08-08 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2020-08-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.